Enspryng reduces risk, severity of relapse in neuromyelitis optica spectrum disorder
Enspryng lowered relapse severity in patients with neuromyelitis optica spectrum disorder, according to data from the double-masked periods of the SAkura phase 3 studies presented at the MSVirtual2020 meeting.
According to a Genentech press release, a post hoc analysis found the risk for severe relapse was reduced by 79% in the group treated with Enspryng (satralizumab-mwge, Genentech) compared with the group treated with placebo.
In a separate pooled analysis of the combined double-masked period and open-label extension, satralizumab reduced relapse risk by 51% compared with those originally in the placebo group.
Additionally, in the double-masked periods, infection rates were lower in the satralizumab-treated group compared with the placebo-treated group in the SAkuraStar study. Infection rates did not differ between groups in the SAkuraSky study.
In August, the FDA approved Enspryng for adults with anti-aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.